A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 276 participants.
Also called NCT06220773
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 276 participants
- Registry
-
NCT06220773
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Indonesia, South Korea
- Registry status
- Recruiting
Technical summary
Registry record NCT06220773. Randomized; double masking; primary purpose treatment. Start 2024-05-21 (actual); primary completion 2026-12 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
- Condition
- Essential Hypertension
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- BR1019A
- Intervention (Drug)
- BR1019B
- Intervention (Drug)
- BR1019C
- Intervention (Drug)
- BR1019A-1
- Intervention (Drug)
- BR1019B-1
- Intervention (Drug)
- BR1019C-1
- Lead sponsor
- Boryung Pharmaceutical Co., Ltd
Record details
- Record id
cardio:ct-nct06220773- Content hash
eaa8a0fcd3b2f264e20d9f5473ace14aef3a4fb54c8d9fe709445d81995f2e8d